

Cure Alzheimer's FUND

Targeting breakthrough research

L E T T E R F R O M T H E C O - F O U N D E R S

Hello friends,

First, a hearty thank you to all of you who have supported us. Your money has been put to good use. The first operating year of Cure Alzheimer's Fund has been most gratifying for the founders, donors, researchers—all of us committed to doing what we can to end the scourge of Alzheimer's disease in our lifetime.



“Our progress
is encouraging
but our biggest
challenges are
ahead.”

Together we've raised about \$3 million from over 425 people. We're funding ten research laboratories in six states working on twelve different, but related, research projects. Our core effort, the Alzheimer's Genome Project (AGP), identifies all genes contributing to increased risk for Alzheimer's disease and is on schedule for completion by the summer of 2008. Additional key projects include understanding more about how the molecular culprit of the disease, A β 42, aggregates to wreak its havoc and an investigation of how certain enzyme inhibitors prevent or decrease the production of A β 42 in the brain.

We've also put together our organization, kept to our operating budget (which is funded entirely by the co-founders, so every dollar donated goes directly to research), and hosted about 400 people at seven thank-you and get-acquainted events in five states.

Our progress is encouraging but our biggest challenges are ahead. Federal funding for Alzheimer's disease has been reduced while the largest population bulge in history is about to hit the danger zone for Alzheimer's disease—65 years and older. About 10% of people over 65 and about half of people over 85 have Alzheimer's disease.

The time is now. A “perfect storm” of factors has converged to facilitate rapid progress in genetic discovery. The mapping of the entire human genome, new technologies that accelerate the identification of specific genes, and the presence of substantial data on families with AD have all combined to make this the right time for significant investment to find the causes and ultimately the cure for this terrible disease.

Our initial collective investment is already paying research dividends. We now need to capitalize on that momentum to sustain the Alzheimer's Genome Project and have the resources available to explore the discoveries that will inevitably and almost immediately come from it.

We have had a great year but it is only the beginning! We hope you'll help us put an end to Alzheimer's Disease.

Henry McCance Jeff and Jacqui Morby Phyllis Rappaport



*Cure Alzheimer's
Fund Co-Founders*

*Top (l to r):
Phyllis Rappaport,
Henry McCance and
Jacqui Morby.*

*Bottom:
Jeff Morby*

Summary of Research

funded by Cure Alzheimer's Fund

In addition to the specific projects listed in this table, the Cure Alzheimer's Fund has also provided funding to the **AlzGene Website** for management and continued development of a publicly available online database that systematically catalogs all genetic association studies in the field of Alzheimer's Disease. The database has already been highly successful with AD researchers as evidenced by several publications citing AlzGene in their research papers.

Funding for 2007:
\$150,000

PROJECT/DESCRIPTION	RESEARCHER(S)	FUNDING
Alzheimer's Genome Project An estimated 3 year, \$3 million project to be completed in the summer of 2008. The project will include genotyping, analyses, follow-up, and confirmatory studies to identify more than 90% of all remaining AD genes thereby providing many more targets for the development of effective therapeutic intervention.	Dr. Rudy Tanzi Massachusetts General Hospital	Funding to date: \$1,212,000
ACAT Inhibitor Study A two-part study focusing on enzyme inhibitors that prevent or decrease the production of Abeta in the brain focusing on the effectiveness of a drug approved for other uses.	Dr. Dora Kovacs Massachusetts General Hospital	First Study - Sept., 2004: \$100,000 Second Study - June, 2005: \$100,000
Alzheimer's Gene Discovery Project This study is characterizing the ability of a novel AD candidate gene for the ability to regulate the enzyme, beta-secretase involved in Abeta production.	Dr. Rudy Tanzi Massachusetts General Hospital	March, 2005: \$138,000
Cure Alzheimer's Fund Research Consortium Collaborative A collaboration of five of the members of the Research Consortium and a member of the Cure Alzheimer's Fund Science Advisory Board hypothesize that an abnormal increase in levels of synaptic Abeta and particularly, Abeta oligomers may lead to synaptic dysfunction, cognitive decline, and eventually dementia. This highly innovative collaborative project will readdresses the amyloid hypothesis by asking which types of Abeta oligomers detrimentally impact synaptic dysfunction and neuronal survival in the brain.	Dr. Charles Glabe, University of California at Irvine <i>The Role of Oligomeric Abeta in Alzheimer's Disease</i>	June, 2006: \$100,000
	Dr. Virginia M.-Y. Lee, University of Pennsylvania <i>Abeta Oligomers in Mouse Models of Alzheimer's Disease</i>	June, 2006: \$100,000
	Drs. Rudolph Tanzi and Robert Moir, Massachusetts General Hospital <i>Identification of agents that inhibit the generation and neurotoxicity of cross-linked Beta amyloid protein species (CAPS)</i>	June, 2006: \$100,000
	Dr. Sangram Sisodia, University of Chicago <i>Molecular Analysis of Abeta*56 Structure and Function</i>	June, 2006: \$100,000
	Dr. Paul Greengard, The Rockefeller University <i>The Role of Oligomeric Abeta in Synaptic Transmission and Plasticity</i>	June, 2006: \$100,000
	Dr. David Holtzman, Washington University <i>Role of Synaptic Activity and Neurotransmitter Modulation in the Dynamic Regulation of Interstitial Fluid Abeta and Oligomer Formation</i>	July, 2006: \$100,000

NEW IRA DONATION OPTIONS

Congress recently passed the Pension Protection Act which allows taxpayers to donate money to charity directly from their IRA account. This year and next (the opportunity ends December 31, 2007), IRA owners who are at least age 70 1/2 can donate up to \$100,000 a year from their retirement accounts, and the gifts count toward the owner's required mini-

imum distribution (RMD). The distributions are tax-free and avoid the penalty on early withdrawals. Donors are not able to claim a tax deduction for the charitable contribution, since the distribution will not be included in taxable income. However, there is a tax break because the money is not included in taxable income as it would be if funds were withdrawn for oneself.

IRA donations offer unique tax savings and can be a convenient way to help Cure Alzheimer's Fund and other charities. Talk with your financial advisor to see if it's a good fit for you or for more information, contact Tim Armour, President, Cure Alzheimer's Fund. tarmour@curealzfund.org or **781-622-2201**.

The AlzGene Database

Cure Alzheimer's is funding the management and continued development of a revolutionary web based database.

AlzGene is a resource for Alzheimer's researchers, providing data and meta-analyses from hundreds of genetic association studies in an easy-to-use, searchable database. Scientists interested in a particular gene can search for it in AlzGene to see what previous studies have reported, receiving a wealth of information in a very short amount of time.

Family history is the second greatest risk factor for Alzheimer's disease after age, and the growing understanding of AD genetics is a critical part of the science behind the disease. In the past decade, literally hundreds of reports have been published claiming or refuting genetic association between AD genes and disease risk, onset age variation, or other phenotypic variables. Presently, more than half a dozen AD association studies are being published monthly from research groups worldwide. For the AD genetics research community (and for the public as well), this wealth of information is becoming increasingly difficult to follow, evaluate and—most importantly—to interpret. The AlzGene database has been developed to manage this huge amount of information and to allow it to be used productively.

The goal of the database is to serve as an unbiased, centralized, publicly available and regularly updated collection of genetic association studies. To date, the database contains detailed summaries of nearly 900 studies on over 360 different genes that have been tested for association with AD. Although the paper describing AlzGene has not yet been published, AlzGene thus far has been highly successful with AD researchers, evidenced by several publications citing AlzGene in their own original research papers.

You can take a peek at the AlzGene website (although you have to be a registered user to search on the site) at <http://www.alzforum.org/res/com/gen/alzgene/default.asp>.

October 15, 2006: Members of Cure Alzheimer's Fund Research Consortium and Scientific Advisory Board member and Nobel Prize Winner Paul Greengard gathered at a Cure Alzheimer's meeting which coincided with the Annual Meeting of Neuroscientists in Atlanta.



From left to right, David Holtzman, John Mazziotta, Virginia Lee, Charles Glabe, Rudy Tanzi, Paul Greengard, and Sam Sisodia.

Financial Report

President Tim Armour reports our progress as follows. Dollars are in cash received and rounded to the nearest \$1,000; no pledges or commitments are included. Please note that the Cure Alzheimer's Fund 2005 tax return, form 990, is now online at www.curealzfund.org.

How much have we raised?

Total funds raised from inception to November 15, 2006:	\$ 3,405,000	100%
---	--------------	------

How are we putting that money to work?

Total distributed for Research from inception to November 15, 2006	\$ 2,550,000	75%
Total operating expenses from inception to November 15, 2006	\$ 500,000	15%*
Reserve before additional research in 2006	\$ 355,000	10%

Projected Research Budget for 2007 \$ 6,000,000

*Provided by the Founders; not paid for by other donors

Cure Alzheimer's FUND

Targeting breakthrough research

Mission Statement

Fund research with the highest probability of slowing, stopping or reversing Alzheimer's disease by 2016.

Research Consortium

Rudolph E. Tanzi, Ph.D., Chairman, Research Consortium,
Harvard Medical School/Massachusetts General Hospital
Charles Glabe, Ph.D., University of California at Irvine
David Michael Holtzman, M.D., Washington University, St. Louis
M. Ilyas Kamboh, Ph.D., University of Pittsburgh
Virginia M.-Y. Lee, Ph.D., MBA, University of Pennsylvania
John C. Mazziotta, M.D. Ph.D., UCLA
Sangram S. Sisodia, Ph.D., University of Chicago

Science Advisory Board

John S. Lazo, Ph.D., University of Pittsburgh
Michael D. Walker, M.D., Retired, National Institutes of Health
Paul Greengard, Ph.D., The Rockefeller University

Board of Directors

Jeffrey L. Morby*, Pittsburgh, PA, Chairman of the Board, Cure Alzheimer's Fund
George A. Davidson, Jr., Pittsburgh, PA
John S. Lazo, Ph.D., Pittsburgh, PA
Henry F. McCance*, Boston, MA
Jacqueline C. Morby*, Pittsburgh, PA
Richard Reed, Pittsburgh, PA
Phyllis Rappaport*, Boston, MA
Edith Shapira, M.D., Pittsburgh, PA
William E. Trueheart, Ed.D., Pittsburgh, PA
*Founder

Administration

Tim Armour, President
Katie Cutler, Director of Operations
Denise Augella, Controller
Anna Kotkin, Intern

Charity Designation

Cure Alzheimer's Fund™ is a "doing business as" name for the Alzheimer's Disease Research Foundation, a 501c3 public charity with federal tax ID # 52-2396428.

Please help us fund research with the highest probability of slowing, stopping or reversing Alzheimer's Disease.

Donations can be made through our website
www.curealzfund.org or sent directly to our office.

For gifts of securities or direct wire transfers, please contact
Tim Armour at **781-622-2201** for further information.